<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02581384</url>
  </required_header>
  <id_info>
    <org_study_id>15-278</org_study_id>
    <nct_id>NCT02581384</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors</brief_title>
  <official_title>Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is studying stereotactic body radiotherapy (SBRT) as a possible treatment&#xD;
      for lung relapse of Ewing sarcoma, rhabdomyosarcoma, osteosarcoma, non-rhabdomyosarcoma soft&#xD;
      tissue sarcoma, Wilms tumor or other primary renal tumor (including clear cell and rhabdoid).&#xD;
      SBRT is a form of targeted radiotherapy that can treat very small tumors using a few large&#xD;
      doses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is a Pilot Study, also known as a Phase I-II study, which means it is the&#xD;
      first time investigators are examining this study intervention for patients with lung&#xD;
      recurrence of Ewing sarcoma, rhabdomyosarcoma, osteosarcoma, nonrhabdomyosarcoma soft tissue&#xD;
      sarcoma, Wilms tumor or other primary renal tumor (including clear cell and rhabdoid). This&#xD;
      study tests the most appropriate dose, safety and efficacy of SBRT for the treatment of lung&#xD;
      recurrence of these cancers in children. Standard radiotherapy is typically used to treat&#xD;
      Ewing sarcoma and is used to treat lung recurrence. SBRT is being used to treat adults with&#xD;
      small inoperable lung cancers; in such cases, SBRT has been shown to be effective and&#xD;
      well-tolerated. SBRT is also used to treat bone metastases in adults and children.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study closed primarily due to weak accrual, as well as study design limitations.&#xD;
  </why_stopped>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">August 2020</completion_date>
  <primary_completion_date type="Actual">August 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Dose Limiting Toxicity [Phase I]</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Dose Limiting Toxicities (DLT's) are toxicities experienced from start of therapy to 6 month. DLT's are assessed on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.&#xD;
DLTs are defined as follows:&#xD;
Grade 2 or higher toxicities:&#xD;
Myelitis&#xD;
Esophageal fistula, perforation, hemorrhage&#xD;
Grade 3 or higher toxicities considered to be a direct result of therapy:&#xD;
Pneumonitis&#xD;
Pericarditis, pericardial effusion&#xD;
Esophageal necrosis, stenosis, ulcer&#xD;
Dyspnea&#xD;
Grade 4 toxicities:&#xD;
Esophagitis&#xD;
Pericardial tamponade&#xD;
Pulmonary toxicity excluding infectious pneumonia&#xD;
Skin toxicity&#xD;
Hemoptysis/pulmonary hemorrhage&#xD;
Grade 5 toxicities, including:&#xD;
Pulmonary toxicity including pneumonitis&#xD;
Excluding infectious pneumonia&#xD;
Three participants will enter the study in each cohort. If 0/3 patients experiences a DLT, this dose level will move forward to the Phase II and more participants will be enrolled.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate [Phase II]</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percentage of participants with response after 6 weeks. Response on treatment was considered to be Complete Response (CR) and Partial Response (PR) measured according Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. For target lesions, CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate [Phase II]</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percentage of pulmonary lesions of participants with response after 6 weeks. Response on treatment was considered to be Complete Response (CR) measured according Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. For target lesions, CR is complete disappearance of all target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Year Local Control Rate [Phase II]</measure>
    <time_frame>24 Months</time_frame>
    <description>Rate of local control (LC) of the index lesion after lung SBRT at 2 years. LC is defined as the absence of tumor progression within 1 cm of the primary tumor site. LC is measured by established methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With 2-Year Failure-Free Survival [Phase II]</measure>
    <time_frame>24 months</time_frame>
    <description>Rate of distant lung failure-free survival defined lung failure or death from any cause at two years. Lung failure defined using established methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Grade 3 or Higher Adverse Events [Phase I and II]</measure>
    <time_frame>Up to 6 months post-treatment (6 months and 2 weeks)</time_frame>
    <description>Grade 3 or higher adverse events as defined by controlled terminology criteria for adverse events (CTCAE) version 4.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Ewing Sarcoma</condition>
  <condition>Rhabdomyosarcoma</condition>
  <condition>Wilms Tumor</condition>
  <condition>Osteosarcoma</condition>
  <condition>Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Nos</condition>
  <condition>Renal Tumor</condition>
  <condition>Rhabdoid Tumor</condition>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <condition>Sarcoma</condition>
  <condition>Sarcoma, Ewing</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1 Dose Level 1 [Phase I]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Wilms tumors or other primary renal tumors. Stereotactic Body Radiotherapy (SBRT) Dose Levels for each target lesion are three 8 Gy fractions for 24 Gy total.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Dose Level 2 [Phase I]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Wilms tumors or other primary renal tumors. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Dose Level 3 [Phase I]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Wilms tumors or other primary renal tumors. SBRT Dose Levels for each target lesion are three 12 Gy fractions for 36 Gy total.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Dose Level 2 [Phase I]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Dose Level 3 [Phase I]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Ewing sarcoma or rhabdomyosarcoma.SBRT Dose Levels for each target lesion are three 12 Gy fractions for 36 Gy total.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Dose Level 2 [Phase II]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiotherapy (SBRT)</intervention_name>
    <arm_group_label>Cohort 1 Dose Level 1 [Phase I]</arm_group_label>
    <arm_group_label>Cohort 1 Dose Level 2 [Phase I]</arm_group_label>
    <arm_group_label>Cohort 1 Dose Level 3 [Phase I]</arm_group_label>
    <arm_group_label>Cohort 2 Dose Level 2 [Phase II]</arm_group_label>
    <arm_group_label>Cohort 2 Dose Level 2 [Phase I]</arm_group_label>
    <arm_group_label>Cohort 2 Dose Level 3 [Phase I]</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Ewing sarcoma, rhabdomyosarcoma, osteosarcoma, non-rhabdomyosarcoma soft&#xD;
             tissue sarcoma, Wilms tumor or other primary renal tumor (including clear cell and&#xD;
             rhabdoid)&#xD;
&#xD;
          -  Age ≤ 21 years;&#xD;
&#xD;
          -  Must be capable of treatment without general anesthesia&#xD;
&#xD;
          -  Lesion size 8 mm - 3 cm&#xD;
&#xD;
          -  Subjects who have lesions within 2 cm of central structures, will be eligible on a&#xD;
             case by-case basis&#xD;
&#xD;
          -  Pulmonary metastases found at relapse (does not have to be first relapse); no more&#xD;
             than 3 lesions per hemi-thorax will be treated but other lesions in the lung may be&#xD;
             present&#xD;
&#xD;
          -  Greater than 5 weeks from doxorubicin at the time of consent, with radiation to be&#xD;
             initiated no less than 6 weeks from doxorubicin&#xD;
&#xD;
          -  Informed consent/assent&#xD;
&#xD;
          -  Life expectancy &gt;3 months&#xD;
&#xD;
          -  Pulmonary Function FEV1 ≥ 50% of predicted;&#xD;
&#xD;
          -  Concurrent immunotherapy is allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior whole-lung or hemi-thorax irradiation of greater than 12 Gy received less than 6&#xD;
             months prior to consent (focal radiotherapy to the thorax is not an exclusion)&#xD;
&#xD;
          -  Lesion larger than 3 cm in diameter&#xD;
&#xD;
          -  Patients for whom surgery would be deemed appropriate rather than radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Marcus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Liu KX, Chen YH, Kozono D, Mak RH, Boyle PJ, Janeway KA, Mullen EA, Marcus KJ. Phase I/II Study of Stereotactic Body Radiation Therapy for Pulmonary Metastases in Pediatric Patients. Adv Radiat Oncol. 2020 Sep 23;5(6):1267-1273. doi: 10.1016/j.adro.2020.09.004. eCollection 2020 Nov-Dec.</citation>
    <PMID>33305087</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 19, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2015</study_first_posted>
  <results_first_submitted>March 5, 2021</results_first_submitted>
  <results_first_submitted_qc>April 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 30, 2021</results_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>Karen J Marcus, MD FACR</investigator_full_name>
    <investigator_title>Karen J Marcus, M.D.</investigator_title>
  </responsible_party>
  <keyword>Ewing Sarcoma</keyword>
  <keyword>Rhabdomyosarcoma</keyword>
  <keyword>Wilms Tumor</keyword>
  <keyword>Rhabdomyosarcoma of Mediastinum</keyword>
  <keyword>Ewing's Sarcoma Metastatic</keyword>
  <keyword>Ewing Family of Tumors</keyword>
  <keyword>Ewing's Tumor Metastatic</keyword>
  <keyword>Osteosarcoma, Metastatic</keyword>
  <keyword>Osteosarcoma in Children</keyword>
  <keyword>Rhabdoid Tumor</keyword>
  <keyword>Lung Metastasis</keyword>
  <keyword>Radiation for Children</keyword>
  <keyword>SBRT for children</keyword>
  <keyword>Stereotactic Body Radiotherapy</keyword>
  <keyword>Pulmonary Metastasis</keyword>
  <keyword>Lung Metastasis in Children</keyword>
  <keyword>Pulmonary Metastasis in Children</keyword>
  <keyword>Comfort Care</keyword>
  <keyword>Palliative Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Wilms Tumor</mesh_term>
    <mesh_term>Rhabdoid Tumor</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT02581384/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>January 2017 to December 2018. No participants were in enrolled in Cohort 1 Dose Level 1 [Phase I], Cohort 1 Dose Level 2 [Phase I], Cohort 1 Dose Level 3 [Phase I], and Cohort 2 Dose Level 3 [Phase I]</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 2 Dose Level 2 [Phase I]</title>
          <description>Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.&#xD;
Stereotactic Body Radiotherapy (SBRT)</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2 Dose Level 2 [Phase II]</title>
          <description>Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.&#xD;
Stereotactic Body Radiotherapy (SBRT)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 2 Dose Level 2 [Phase I and II]</title>
          <description>Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.&#xD;
Stereotactic Body Radiotherapy (SBRT)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12" lower_limit="7" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Tumor Histologies</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Ewing Sarcoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Anaplastic Chordoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Osteosarcoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Lesions</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Two Lesions</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>One Lesion</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Dose Limiting Toxicity [Phase I]</title>
        <description>Dose Limiting Toxicities (DLT's) are toxicities experienced from start of therapy to 6 month. DLT's are assessed on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.&#xD;
DLTs are defined as follows:&#xD;
Grade 2 or higher toxicities:&#xD;
Myelitis&#xD;
Esophageal fistula, perforation, hemorrhage&#xD;
Grade 3 or higher toxicities considered to be a direct result of therapy:&#xD;
Pneumonitis&#xD;
Pericarditis, pericardial effusion&#xD;
Esophageal necrosis, stenosis, ulcer&#xD;
Dyspnea&#xD;
Grade 4 toxicities:&#xD;
Esophagitis&#xD;
Pericardial tamponade&#xD;
Pulmonary toxicity excluding infectious pneumonia&#xD;
Skin toxicity&#xD;
Hemoptysis/pulmonary hemorrhage&#xD;
Grade 5 toxicities, including:&#xD;
Pulmonary toxicity including pneumonitis&#xD;
Excluding infectious pneumonia&#xD;
Three participants will enter the study in each cohort. If 0/3 patients experiences a DLT, this dose level will move forward to the Phase II and more participants will be enrolled.</description>
        <time_frame>Up to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2 Dose Level 2 [Phase I]</title>
            <description>Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.&#xD;
Stereotactic Body Radiotherapy (SBRT)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose Limiting Toxicity [Phase I]</title>
          <description>Dose Limiting Toxicities (DLT's) are toxicities experienced from start of therapy to 6 month. DLT's are assessed on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.&#xD;
DLTs are defined as follows:&#xD;
Grade 2 or higher toxicities:&#xD;
Myelitis&#xD;
Esophageal fistula, perforation, hemorrhage&#xD;
Grade 3 or higher toxicities considered to be a direct result of therapy:&#xD;
Pneumonitis&#xD;
Pericarditis, pericardial effusion&#xD;
Esophageal necrosis, stenosis, ulcer&#xD;
Dyspnea&#xD;
Grade 4 toxicities:&#xD;
Esophagitis&#xD;
Pericardial tamponade&#xD;
Pulmonary toxicity excluding infectious pneumonia&#xD;
Skin toxicity&#xD;
Hemoptysis/pulmonary hemorrhage&#xD;
Grade 5 toxicities, including:&#xD;
Pulmonary toxicity including pneumonitis&#xD;
Excluding infectious pneumonia&#xD;
Three participants will enter the study in each cohort. If 0/3 patients experiences a DLT, this dose level will move forward to the Phase II and more participants will be enrolled.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate [Phase II]</title>
        <description>Percentage of participants with response after 6 weeks. Response on treatment was considered to be Complete Response (CR) and Partial Response (PR) measured according Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. For target lesions, CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter.</description>
        <time_frame>6 weeks</time_frame>
        <population>It is pre-specified in the protocol that Phase I and Phase II populations for each cohort are combined for this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2 Dose Level 2 [Phase I and II]</title>
            <description>Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.&#xD;
Stereotactic Body Radiotherapy (SBRT)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate [Phase II]</title>
          <description>Percentage of participants with response after 6 weeks. Response on treatment was considered to be Complete Response (CR) and Partial Response (PR) measured according Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. For target lesions, CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter.</description>
          <population>It is pre-specified in the protocol that Phase I and Phase II populations for each cohort are combined for this analysis</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="54.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response Rate [Phase II]</title>
        <description>Percentage of pulmonary lesions of participants with response after 6 weeks. Response on treatment was considered to be Complete Response (CR) measured according Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. For target lesions, CR is complete disappearance of all target lesions.</description>
        <time_frame>6 weeks</time_frame>
        <population>It is pre-specified in the protocol that Phase I and Phase II populations for each cohort are combined for this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2 Dose Level 2 [Phase I and II]</title>
            <description>Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.&#xD;
Stereotactic Body Radiotherapy (SBRT)</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response Rate [Phase II]</title>
          <description>Percentage of pulmonary lesions of participants with response after 6 weeks. Response on treatment was considered to be Complete Response (CR) measured according Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. For target lesions, CR is complete disappearance of all target lesions.</description>
          <population>It is pre-specified in the protocol that Phase I and Phase II populations for each cohort are combined for this analysis</population>
          <units>percentage of pulmonary lesions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="39" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2 Year Local Control Rate [Phase II]</title>
        <description>Rate of local control (LC) of the index lesion after lung SBRT at 2 years. LC is defined as the absence of tumor progression within 1 cm of the primary tumor site. LC is measured by established methods.</description>
        <time_frame>24 Months</time_frame>
        <population>It is pre-specified in the protocol that Phase I and Phase II populations for each cohort are combined for this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2 Dose Level 2 [Phase I and II]</title>
            <description>Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.&#xD;
Stereotactic Body Radiotherapy (SBRT)</description>
          </group>
        </group_list>
        <measure>
          <title>2 Year Local Control Rate [Phase II]</title>
          <description>Rate of local control (LC) of the index lesion after lung SBRT at 2 years. LC is defined as the absence of tumor progression within 1 cm of the primary tumor site. LC is measured by established methods.</description>
          <population>It is pre-specified in the protocol that Phase I and Phase II populations for each cohort are combined for this analysis</population>
          <units>percentage of pulmonary lesions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="19" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With 2-Year Failure-Free Survival [Phase II]</title>
        <description>Rate of distant lung failure-free survival defined lung failure or death from any cause at two years. Lung failure defined using established methods.</description>
        <time_frame>24 months</time_frame>
        <population>It is pre-specified in the protocol that Phase I and Phase II populations for each cohort are combined for this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2 Dose Level 2 [Phase I and II]</title>
            <description>Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.&#xD;
Stereotactic Body Radiotherapy (SBRT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With 2-Year Failure-Free Survival [Phase II]</title>
          <description>Rate of distant lung failure-free survival defined lung failure or death from any cause at two years. Lung failure defined using established methods.</description>
          <population>It is pre-specified in the protocol that Phase I and Phase II populations for each cohort are combined for this analysis</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Grade 3 or Higher Adverse Events [Phase I and II]</title>
        <description>Grade 3 or higher adverse events as defined by controlled terminology criteria for adverse events (CTCAE) version 4.</description>
        <time_frame>Up to 6 months post-treatment (6 months and 2 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2 Dose Level 2 [Phase I]</title>
            <description>Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.&#xD;
Stereotactic Body Radiotherapy (SBRT)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 Dose Level 2 [Phase II]</title>
            <description>Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.&#xD;
Stereotactic Body Radiotherapy (SBRT)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3 or Higher Adverse Events [Phase I and II]</title>
          <description>Grade 3 or higher adverse events as defined by controlled terminology criteria for adverse events (CTCAE) version 4.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 months post-treatment (6 months and 2 weeks)</time_frame>
      <desc>Serious Adverse Events (SAE's) were defined as events with treatment-attribution of possibly, probably or definitely and grade 3 or higher. All remaining AEs are classified as Other AEs (OAE) including grade 3 or higher events with treatment-attribution of unlikely and unrelated plus all grade 1 and 2 events. Maximum grade toxicity by type was then calculated within SAE and OAE datasets. No further data is available to specify classification of other beyond the general term.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 2 Dose Level 2 [Phase I]</title>
          <description>Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.&#xD;
Stereotactic Body Radiotherapy (SBRT)</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2 Dose Level 2 [Phase II]</title>
          <description>Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.&#xD;
Stereotactic Body Radiotherapy (SBRT)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCA v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE v4.0">Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study had small sample size / weak accrual.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Karen Marcus MD</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>16177328783</phone>
      <email>karen_marcus@dfci.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

